Hong Kong Retail & Wholesale Drug Licensing Guide

The four licences cover different products, transaction methods and designated premises. Complete a business-pathway matrix first to avoid conflating retail, wholesale, import, export, Chinese medicine and manufacturing boundaries in a single application.

[Official / regulatory position] ASP is the registration of designated premises for western-medicine retail; LSP is the retail regime for Part II poisons; WDL covers wholesale of pharmaceutical products and/or poisons and requires GDP to be implemented when dealing in pharmaceutical products; 1C covers only wholesale of proprietary Chinese medicines (pCM). If you plan to wholesale, trade across borders, market products, handle antibiotics or dangerous drugs, deal in Chinese herbal medicines, or manufacture, each actual activity must be assessed against its own separate regime. Coverage cannot be assumed merely because the company name or address is the same, or because all the goods are described as “medicines”.

[Practical recommendation] Before selecting premises, signing a lease, placing a purchase order or signing a letter of intent for an acquisition, prepare a matrix of “product / ingredient or category — customer — transaction method — ownership of goods — inventory location — proposed licence — additional permits — person responsible”. This matrix serves as the working document for defining the application scope and should also be used to approve new SKUs, channels or suppliers before they go live.

[Risk alert] “Pharmacy”, “medicine shop”, “wholesale”, “Chinese medicine” and “health products” are commercial descriptions, not complete regulatory classifications. Manufacturing is not covered in this guide. If actual operations involve manufacturing, batch release or GMP, refer to the existing manufacturer details page on this site; do not apply WDL PIC, ASP pharmacist or 1C principal staff requirements interchangeably.

Swipe horizontally to view all items

A licence application is not assessed solely on company registration documents. The competent authority cross-checks the applicant entity, occupation of the premises, directors / proprietor / partners, signing authority, employment, inventory and actual operating arrangements.

[Official / regulatory position] None of the four routes is restricted to Hong Kong limited companies. The verified materials for ASP, LSP, WDL and 1C each specify corresponding document requirements for companies, sole proprietors or partnerships. The business structure should therefore support actual operations, the lease, employment and governance. If a company is used, company registration, Business Registration and director details must be ready before applying in its name; company registration does not itself confer permission to operate.

[Document methodology] Each application should use a single, consistent “entity factsheet” linking the company or Business Registration, lease / warehouse agreement, list of directors / proprietor / partners, key personnel, purchasing signatory authority, inventory owner, payment-receiving entity and actual control arrangements. ASP and LSP also pay particular attention to the relationship between the applicant and the premises; WDL and 1C likewise require consistency in entity, key personnel and premises information.

[Risk alert] Nominee directors, undisclosed actual managers, an applicant entity that does not match the lease, or an assessment of licensing implications deferred until after the transaction will all increase the risk of suitability concerns, requests for further information and inspection. Do not describe filings with the Companies Registry, updates to Business Registration or the coming into effect of a shareholders’ agreement as meaning that the matter has already been accepted for drug-regulatory purposes.

Swipe horizontally to view all items

Personnel requirements vary by licence type. Treating retail pharmacists, WDL PIC / GDP RP, manufacturer AP, LSP persons-in-charge and 1C principal staff as interchangeable qualifications leads to errors in application representations and on-site operations.

[ASP duty coverage and actual control] The PIC must be a person considered suitable by the Board, but cannot replace a registered pharmacist in carrying out personal control, professional supervision or prescription dispensing duties. On every business day, a registered pharmacist must be physically present and exercise control and supervision for at least two-thirds of the business hours. This cannot be averaged over a week or month, nor replaced by telephone standby or remote supervision.

[Limits on sales when a pharmacist is not present] When a registered pharmacist is not physically present, Part I poisons, antibiotics or dangerous drugs must not be sold or dispensed; neither the PIC nor a shop assistant can act as a substitute. Retail sale of Part II poisons is restricted to an ASP or LSP premises; pharmaceutical products containing no poisons may be sold at general retail outlets. Both must still comply SKU by SKU with the actual classification, Hong Kong registration, labelling and other applicable requirements; “non-prescription” alone is not sufficient for release for sale. Arrangements for locked cabinets, sales suspension, handover, record-keeping and escalation should be set out in SOPs, but an SOP cannot replace the requirement for a pharmacist to be present.

[LSP, WDL and 1C] An LSP must have a person who actually manages the business, but current materials do not require that person invariably to be a registered pharmacist or to hold a uniform pharmaceutical qualification. A WDL must have an approved PIC, who is also the GDP RP when dealing in pharmaceutical products; a registered pharmacist is required only for specified special scopes, such as listed psychotropic substances or certain dangerous drugs. A 1C application should identify principal staff covering purchasing, receipt, storage and issue; AP, nominated person or registered pharmacist requirements should not be imposed without a basis.

[Practical recommendations and risks] The appointment letter should specify concrete responsibilities for receipt of goods, product classification, keys or access control, temperature and humidity, prescriptions/records, deviations, complaints, recalls, training and regulatory liaison. A consultant can assist with document preparation, mock Q&A and milestone tracking, but cannot replace the PIC, RP, registered pharmacist or key staff in carrying out professional and statutory duties. Rengangyongsheng (Hong Kong) Limited and Drew Tang provide application coordination and explanations of compliance information; they do not practise as registered pharmacists or replace licensed personnel in carrying out their professional duties.

Swipe horizontally to view all items

All four licence types are based on actual premises, but the level of control differs. Plans, equipment, inventory, personnel practices and record locations must correspond with one another during an inspection.

[Retail premises] The ASP dispensing area must be separated from other areas and access by customers restricted. Depending on the actual products, dedicated locked medicine refrigerators maintained at 2°C to 8°C, locked cabinets and key controls are required. Part I poisons, antibiotics, psychotropic substances and dangerous drugs are subject to corresponding locked-storage requirements. LSP premises must provide suitable storage, lighting, ventilation and air conditioning. The name, licence and notice stating that antibiotics must not be sold should be displayed outside the shop / in the retail area in accordance with the Code of Practice; signs or symbols implying a pharmacy or ℞ must not be used.

[Wholesale storage] A WDL should design receiving, quarantine, released-goods, returns, dispatch, temperature and humidity, and access controls according to product label conditions, volume and risk. Cold-chain arrangements must also address mapping, routine monitoring, calibration, alarms and contingency plans. 1C premises must be hygienic, with space and shelving / cabinets proportionate to the storage volume, and measures against insects, rodents, damp and mould, as well as clearly defined and explainable statuses for goods pending examination, exceptions, returns and released goods.

[Risk alert] None of the published materials for the four licence types sets a uniform minimum floor area or minimum paid-up capital for all applicants. Having leased a warehouse, installed a general-purpose refrigerator or submitted plans does not mean the premises have been accepted. Changes to the address, additional warehouses, layout, cold chain or storage facilities cannot automatically rely on the original approval.

Swipe horizontally to view all items

Submitting an application is not permission to commence operations, nor should it be the starting point for the project. A more prudent approach is to first finalise the factual baseline, then complete the official application pack, on-site demonstration and follow-up submissions.

[Stage 1: Scope and official documents] Use the latest application forms, checklists and fee arrangements available at the time of submission, and provide entity, Business Registration, director/sole proprietor/partner, relevant personnel, premises plans and business information as required for the licence type. An ASP application must include the registered pharmacist’s details and required attachments in accordance with the official forms in force at the time. Product classification lists, duty arrangements, prescription/dispensing procedures and relevant SOPs are recommended as supporting materials for interviews, inspections and ongoing operations. Whether they must accompany the application depends on the forms in force at the time and the Drug Office’s case-specific requirements. A WDL application has separate PIC/deputy PIC, supply chain and GDP documentation requirements. For 1C, use Form 1C and Checklist 2C, and maintain separate product registration and import/export files.

【Stage 2: Premises and personnel】For ASP, the usual process is an interview with the PIC and pharmacist, followed by an inspection by a pharmacist inspector; LSP applications involve a premises inspection and consideration by the relevant committee; for WDL, a pre-licensing inspection is conducted once the documents are considered satisfactory, and the committee may interview the PIC / deputy PIC; for 1C, a premises inspection is arranged after acknowledgement of receipt, followed by consideration by the Chinese Medicines Board. Inspections focus not on the appearance of the fit-out, but on consistency between the premises, actual responsibilities, products, storage, records and declarations.

【Stage 3: Further information and decision】For each query, maintain a log recording “question — official basis / facts — supporting documents — on-site location — person responsible — submission date — evidence of closure”. If further information changes the applicant entity, personnel, premises or scope, also review the related plans, SOPs, training, product master files and application forms. The competent authority makes the final decision on approval, conditions or refusal on a case-by-case basis.

Swipe horizontally to view all items

Government fees, government service targets, a business’s premises and personnel costs, third-party testing / validation costs, and consultancy service fees are different categories. Any external quotation or transaction budget should clearly state its source and exclusions.

【Government fees】Verified information lists the initial ASP premises registration fee as HK$1,000 and the renewal registration fee as HK$1,310; the LSP initial application fee as HK$455 and annual retention fee as HK$430; the WDL application fee as HK$625, the Wholesale Dealer Licence for supplying dangerous drugs as HK$860, the Antibiotics Permit as HK$450, and changes to particulars as HK$155 per licence (where applicable); and the 1C licence fee as HK$1,210, renewal fee as HK$1,050 and address change fee as HK$805. Amounts and payment arrangements should always be rechecked against the official forms, legislation and payment notice applicable at the time of submission.

[How to Interpret Timeframes Correctly] The two-month service pledge in the current ASP application form and guidance is conditional on the applicant and key personnel having good criminal and disciplinary records and sound financial standing, and on satisfactory results at the first interview assessment (if applicable) and first inspection. The LSP two-month service pledge is subject to conditions including suitable premises, the records of relevant personnel and a satisfactory first inspection. The WDL two-month target is conditional on complete documentation and adequate, satisfactory storage facilities; it does not specify two working months or a fixed starting point. None of these is an unconditional or statutorily guaranteed timeframe. The 30 days for 1C concern acknowledgment of receipt, not approval time; a new 1C licence is valid for two years, and renewal applications should be submitted no less than six months before expiry.

[Service estimates and basis of quotations] The service packages on this website give estimated project coordination periods of approximately 10–12 months for a western medicine wholesale licence and approximately 3–4-plus months for a wholesaler licence in proprietary Chinese medicines. These estimates do not indicate government processing times or a fixed licence issue date. Government fees, consultancy service fees, premises deposits, monthly maintenance fees and their currencies should be specified separately in the relevant quotation or written proposal. Unless expressly confirmed, “元” in a service package should not automatically be understood as Hong Kong dollars. The consultant cannot guarantee approval, no requests for further information, or priority processing.

Swipe horizontally to view all items

Holding a licence is not a one-off status. Day-to-day sales, receipt of goods, storage, temperature and humidity, expiry dates, complaints, recalls, training and inspections should be linked in the same tracking system. Record retention periods should be determined separately according to licence type and product scope.

[Retail maintenance and practical self-checks] An ASP should check daily that the pharmacist is physically present, and review locked cabinets, the cold chain, prescriptions/registers and unusual stock. Prescription, register and related supporting documents are generally subject to a two-year retention requirement. An LSP should rely on original packaging, batch numbers, expiry dates, compliant suppliers and receiving documents, check expiry dates regularly, and immediately segregate recalled or expired products. Purchase orders, delivery notes or invoices must be retained for two years from the date of issue or until the product expires, whichever is later.

【Wholesale maintenance】WDL should implement a GDP quality system covering product / supplier / customer qualification, receipt, quarantine, temperature and humidity, calibration, deviations, CAPA, complaints, returns, recalls, outsourcing, training, self-inspection and management review. Transactions involving Part I poisons or pharmaceutical products must be recorded within 72 hours of taking place, with proof of receipt collected where applicable. The WDL two-year record retention period, the minimum five-year retention period for general GDP documents and electronic backups, the 30-year retention period for ATP, and the separate retention period for active substances must not be conflated.

【Proprietary Chinese medicines maintenance】For 1C, establish an end-to-end process covering suppliers, acceptance, product name / specification / batch number / quantity / expiry date, manufacturer’s storage instructions, incidents and segregation of returned goods, dispatch, and complaints / recalls. Transaction documents must be kept at the premises to which the licence relates for at least two years after the transaction date, and batch numbers must enable traceability to the source and destination.

Swipe horizontally to view all items

Procedures and timing differ by type of change. Treating all changes as requiring notification “within one month”, or assuming that shareholders, addresses, directors, PICs and warehouses are all subject to the same rules, would distort the compliance assessment.

【ASP and LSP】ASP should be renewed in accordance with the certificate expiry date and official notice, and a list of the premises address and personally controlled pharmacists should be submitted every January. Changes to the address or layout, and changes in ownership, partnership, directors or PIC, require the Board’s approval before implementation. LSP fees must be paid annually; any change to the sole proprietor, partnership or directors requires the Board’s prior approval. Do not assume a fixed timeframe for individual LSP cases involving general shareholder changes or relocation; first confirm the applicable procedure with the Drug Office.

【WDL】Annual renewal does not replace notification of changes during the year. The Committee must be notified in writing within one month after a change of director / sole proprietor / partner. Changes to the PIC, DPIC and dangerous drugs PIC require prior approval. Details and supporting evidence must be submitted for changes to the business address, additional warehouse, storage facilities, cold-chain equipment or layout; maintain the existing approved arrangements until approval is obtained. The current checklist does not include a separate one-month requirement for a shareholder-only change.

【1C】Renewal should be applied for no less than six months before expiry. Differences in directors, persons-in-charge or file details should be notified to the Chinese Medicines Board as soon as possible and reflected in the renewal documents. An address change must be applied for well in advance and no later than the third day after the change occurs, and the business may operate at the new address only after approval is obtained. An unapproved address change may result in the licence becoming invalid when one month has elapsed.

Swipe horizontally to view all items

Buying and selling a “licensed company” does not amount to buying and selling a freely transferable licence. The transaction should first establish who will continue operating after completion, at which approved premises, and with what personnel and quality system; only then should the commercial structure and regulatory steps be arranged.

【Pre-transaction due diligence】Check the licence type, licensed entity, certificate or licence number, expiry date, conditions / restrictions, registered address, additional warehouses, personnel, product scope, product registration or authorisation chain, import and export accounts, stock status, temperature and humidity records and calibration, prescriptions / registers or GDP documents, complaints / recalls / CAPA, renewals, requests for further information and regulatory correspondence. Assess stock value separately from its saleability; near-expiry, recalled, quarantined, temperature-control deviation or goods of unknown source must not be treated as normal saleable stock.

【Conditions precedent and completion】List any changes requiring prior approval or written confirmation—directors, sole proprietor / partnership, PIC, pharmacist cover, address, warehouse, storage facilities or licence particulars—as conditions precedent or expressly documented transitional arrangements. At completion, obtain signed inventory records for stock, batch numbers and expiry dates, and hand over access to medicine cabinets / entry systems / alarms, original records, system access, supplier and customer details, outstanding quality incidents and the next renewal date. Record retention and responsibility for regulatory communications must not be interrupted by a shareholding change.

【Post-completion】Complete the identified notifications, approvals, renewals, address / warehouse applications, product registration details or import and export licence arrangements, and conduct a management review. Whether the transaction involves 100% of the shares, a partial shareholding, assets or a business, it must not be promoted as an automatic licence transfer or automatic regulatory consent. Conversely, without a basis, do not claim that every change involving shareholders only necessarily requires the same type of approval.

Swipe horizontally to view all items

Online listings, orders, payment, delivery, storage and cross-border freight must all be assessed by reference to the legal facts of the actual sale, possession, delivery, import, export and promotion. Operating licences, product registration and documents for each shipment should be managed separately.

[Western medicines online and product boundaries] Promotion or acceptance of orders online by an ASP or LSP does not reduce the requirements for poison-sale classification, prescriptions, pharmacist presence, designated premises, original packaging, registration or advertising. An LSP must not use its website, platforms, social media, shop signs or staff titles to imply that it is a pharmacy or is supervised by a registered pharmacist. Pharmaceutical products sold, offered for sale, distributed or possessed for that purpose in Hong Kong generally must first be registered (except where an applicable exemption applies); an operating licence is not a registration certificate for any SKU.

[Western medicines cross-border] A WDL does not mean that imports or exports may be made continuously without further requirements. An application using Form 3 / Form 6 must be made separately for each import or export of pharmaceutical products; contracts and shipping documents should separately identify the licensed entity, registration certificate holder or authorisation chain, licence applicant, consignee, storage provider, carrier and batch number. An ASP or LSP does not thereby acquire wholesale or import/export qualifications by purchasing stock for its premises.

[Proprietary Chinese medicines: products and cross-border trade] Unregistered proprietary Chinese medicines must not be sold, imported or possessed in Hong Kong (unless an applicable exemption applies); labels, package inserts, sales packaging and registration particulars each form a separate compliance chain. A 1C does not replace the import/export licence required for each shipment of proprietary Chinese medicines; documents for different purposes, such as re-export, registration, testing or packaging, should be prepared according to the circumstances. The general target of 2 working days once all documents are in order applies only to the import/export licence service for proprietary Chinese medicines, not to 1C or product registration approval times.

Swipe horizontally to view all items

The value of professional services lies in organising complex facts into auditable evidence and identifying dependencies in advance; they cannot replace decisions by the regulatory authorities or the on-site duties of statutory key personnel.

[Project support available] Rengangyongsheng (Hong Kong) Limited can assist with route assessment, identifying information gaps, mapping entity–personnel–premises relationships, indexing application documents, preparing product and goods-flow matrices, cross-checking plans and SOPs, mock inspections, tracking supplementary information, renewal calendars and transaction due diligence / handover checklists. This work is intended to reduce rework caused by inconsistent documents, unprepared premises, unidentified product boundaries and unclear responsibility for supplementary information.

[Responsibilities that cannot be replaced] Applicants, directors / sole proprietors / partners, PICs, GDP RPs, registered pharmacists, persons in charge of LSPs and principal officers of 1Cs must take responsibility for their truthful declarations, professional judgement and actual operations. A consultant cannot make factual declarations on behalf of personnel, exercise actual control over controlled medicines, assume the duties of a pharmacist or PIC, or present internal training as an officially recognised qualification.

[Timing and communications] Any service plan should separately set out government fees, consultancy services, client preparation obligations, third-party costs, official service targets and estimates for items that are not guaranteed. External descriptions should use only accurate wording such as “assist with preparation, coordination and follow-up” and “reduce rework”; do not use “guaranteed approval”, “guaranteed within two months”, “internal fast track” or any suggestion of government acceleration.

Swipe horizontally to view all items

The handbook brings together the different requirements in the four detailed pages under a single project governance framework. The sequence below is not a promise of an approval timeline; it arranges dependencies to reduce rework.

[Step 1: Establish the facts] Confirm the intended activities, product matrix, customers and suppliers, retail / wholesale / cross-border model and proposed premises; select the ASP, LSP, WDL, 1C or combined route accordingly. If the entity is a company, complete the relevant company and Business Registration particulars; if both western medicines and proprietary Chinese medicines are involved, maintain separate files under Chapter 138 and Chapter 549.

[Step 2: Build the evidence] Identify key personnel and deputies, premises and storage layout, products and supply chain, SOPs, and quality and record-keeping systems; use the official application form and checklist as the main index, linking each declaration to supporting documents, signatories, versions and on-site locations. Submit only once this is complete, and attend interviews or inspections in the actual state of readiness.

[Step 3: Governance after approval] Include licence conditions, expiry dates, personnel qualifications, premises / warehouses, product registrations and trade licences, record retention, complaints and recalls, GDP or proprietary Chinese medicine quality controls, changes and transaction matters in a single compliance register. The first management review should confirm that the site, stock, documents and external representations are consistent with the approved status; new SKUs, channels, relocations and transactions should first undergo a change impact assessment.

Swipe horizontally to view all items